Press releases and articles

First newly developed ELISA of risk class B declared IVDR-compliant

After EUROIMMUN received the required certificate for its quality management system in accordance with the new European Regulation (EU) 2017/746 on in vitro diagnostic medical devices (IVDR) in May of ...

Dried blood spots provide easy, reliable antibody testing

Dried blood spots (DBS) collected from the fingertip yield reliable results in analysis of anti-SARS-CoV-2 antibodies, even after prolonged storage of DBS eluates for 6 to 8 hours. This was ...

Omicron-induced T- and B-cell immunity in vaccinated and naïve individuals

A recent study has demonstrated substantial differences in SARS-CoV-2 immunity after Omicron infection in triple-COVID-19-vaccinated and antigen-naïve individuals, which may influence cross-protection ...

Schleswig-Holstein’s Minister of Economic Affairs visits EUROIMMUN

Claus Ruhe Madsen, Minister of Economic Affairs, Transport, Employment, Technology and Tourism of the German state of Schleswig-Holstein, together with Dr. Jürgen Walkenhorst and Dr. Georg Eschenburg ...

A life-saving diagnosis thanks to comprehensive antibody testing – a motivating success story

In our latest video, Mr Mende tells us how autoantibody determination completely changed his prognosis. For the past six years, Mr Mende has suffered from necrotising myositis, an autoimmune disease ...

EUROIMMUN receives IVDR certificate

Availability of EUROIMMUN products in the EU secured

On May 10, 2023, EUROIMMUN received the certificate for its quality management system according to the new European Regulation on in vitro ...

UNIQO 160 – from primary sample to final result

The UNIQO 160 embodies the next generation of fully automated systems for indirect immunofluorescence diagnostics.
What is behind it?

UPDATE - The perfect match for routine laboratories of all sizes

Updated Video!

Our parent company reveals its new name and brand

As the capstone in a multi-year transformation process, on May 9th, our parent company unveiled its new name and brand – Revvity.

Novel autoantibody against septin-3 discovered in neurological disease

The cytoskeleton protein septin-3 has been identified as a novel target antigen of autoantibodies in patients with paraneoplastic cerebellar ataxia. The new biomarker was discovered in a collaborative ...

Back to top